Summary
In the past, therapy of hypertension has not provided protection against coronary heart disease. The possible reasons are multiple and likely will never be fully ascertained. Nonetheless, numerous changes in therapy can be made that should reduce coronary risk. These include more careful monitoring of the blood pressure with particular care for control of high levels during the early morning hours; attention to all alterable risk factors with care to avoid worsening of other risks with antihypertensive drugs; adroit use of nondrug therapies; and, when drugs are used, the pressure should be lowered slowly and only to a level that avoids coronary hypoperfusion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335: 827–838.
Cutler JA, MacMahon SW, Furberg CD. Controlled clinical trials of drug treatment for hypertension. A review. Hypertension 1989;13(Suppl I):I36-I44.
Payer L. Medicine & Culture: Varieties of Treatment in the United States, England, West Germany, and France, New York: Henry Holt and Company, 1988.
McClellan W, Neel J, Owen S. Correlates of drug therapy of diastolic blood pressure between 80–89 mmHg by physicians in the community. Am J Hypertens 1989;2:869–871.
Smith TDW, Clayton D. Individual variation between general practitioners in labelling of hypertension. Br Med J 1990;300:74–75.
Kaplan NM. Clinical Hypertension, 5th ed. Baltimore: Williams & Wilkins, 1990.
Smith WCS, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: The rule of halves. Br Med J 1990;30:981–983.
National High Blood Pressure Education Program Coordinating Committee. Diagnosis and management of hypertension—1987. A nationwide survey of physicians' knowledge, attitudes, and reported behavior. U.S. Department of Health and Human Services; NIH Publication No. 89-2968, 1989.
Jennings GL, Sudhir K. Initial therapy of primary hypertension. Med J Aust 1990;152:198–203.
IMS. Ambler PA, 1990, personal communication.
WHO/ISH Mild Hypertension Liaison Committee. 1989 guidelines for the management of mild hypertension: Memorandum from a WHO/ISH meeting. J Hypertens 1989;7: 689–693.
Argentino C, Toni D, Rasura M, et al. Circadian variation in the frequency of ischemic stroke. Stroke 1990;21:387–389.
Lasco RA, Curry RH, Dickson VJ, et al. Participation rates, weight loss, and blood pressure changes among obese women in a nutrition-exercise program. Public Health Rep 1989;104:640–646.
Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. Br Med J 1990;300: 975–978.
Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. Br Med J 1988;297:1227–1230.
Farnett L, Mulrow CD, Linn WD, et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? JAMA 1991;265:489–495.
Ganten D. World Hypertension League Newsletter, April 1990.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kaplan, N.M. New approaches to the treatment of hypertension. Cardiovasc Drug Ther 5, 973–978 (1991). https://doi.org/10.1007/BF00143522
Issue Date:
DOI: https://doi.org/10.1007/BF00143522